Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
Portfolio Pulse from
Merck's Keytruda and Eisai's Lenvima, combined with chemotherapy, did not improve overall survival in esophageal cancer patients in a late-stage trial.
January 24, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eisai's Lenvima, in combination with Merck's Keytruda and chemotherapy, did not improve overall survival in esophageal cancer patients in a late-stage trial.
The trial failure may lead to a negative short-term impact on Eisai's stock as it could affect perceptions of Lenvima's effectiveness in treating this cancer type.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Merck's Keytruda, in combination with Eisai's Lenvima and chemotherapy, failed to improve overall survival in esophageal cancer patients in a late-stage trial.
The failure of Keytruda in a late-stage trial could negatively impact Merck's stock price as it may affect investor confidence in the drug's efficacy for this cancer type.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80